Peter Valent. 2011. “Severe Adverse Events Associated With the Use of Second-Line BCR/ABL Tyrosine Kinase Inhibitors: Preferential Occurrence in Patients With Comorbidities”. Haematologica 96 (10). Pavia, Italy, 1395-97. https://doi.org/10.3324/haematol.2011.052076.